Roger N. Gunn

Q: What Schools Are Affiliated With Roger N. Gunn

Roger N. Gunn is affiliated with the following schools: University of Warwick, University of California, Berkeley, McGill University, Yale University, Imperial College London, California Institute of Technology, Stanford University

Roger N. Gunn's AcademicInfluence.com Rankings

Roger N. Gunn

Physics

#7251

World Rank

#9270

Historical Rank

Particle Physics

#368

World Rank

#385

Historical Rank

physics Degrees

Download Badge

Physics

Roger N. Gunn's Degrees

PhD Physics University of California, Berkeley
Masters Physics Stanford University

Why Is Roger N. Gunn Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roger N. Gunn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands (2007) (1854)
Evidence for striatal dopamine release during a video game (1998) (1205)
Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model (1997) (1073)
In-vivo measurement of activated microglia in dementia (2001) (1011)
Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient (1999) (723)
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. (2000) (642)
Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. (2000) (640)
An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 (2011) (628)
Positron Emission Tomography Compartmental Models (2001) (461)
Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomy (2011) (372)
Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands (2011) (324)
Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. (2006) (324)
Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET (1998) (290)
GAN Augmentation: Augmenting Training Data using Generative Adversarial Networks (2018) (287)
Connectivity-based functional analysis of dopamine release in the striatum using diffusion-weighted MRI and positron emission tomography. (2014) (271)
Dopamine Transmission in the Human Striatum during Monetary Reward Tasks (2004) (261)
Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK11195 (2000) (252)
Positron emission tomography molecular imaging for drug development. (2012) (244)
Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited (2010) (239)
Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals (1998) (238)
Positron Emission Tomography Compartmental Models: A Basis Pursuit Strategy for Kinetic Modeling (2002) (233)
[11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy (2003) (224)
[11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen’s encephalitis (1999) (213)
Two Binding Sites for [3H]PBR28 in Human Brain: Implications for TSPO PET Imaging of Neuroinflammation (2010) (207)
Huntington's disease progression. PET and clinical observations. (1999) (194)
Positron Emission Tomography Partial Volume Correction: Estimation and Algorithms (2002) (188)
Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates (1999) (185)
In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. (2001) (180)
Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist (2010) (149)
A Database of [11C]WAY-100635 Binding to 5-HT1A Receptors in Normal Male Volunteers: Normative Data and Relationship to Methodological, Demographic, Physiological, and Behavioral Variables (2002) (149)
Within-Subject Comparison of [11C]-( + )-PHNO and [11C]raclopride Sensitivity to Acute Amphetamine Challenge in Healthy Humans (2012) (148)
Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers (2001) (129)
Positron emission tomography imaging of amphetamine‐induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride (2009) (129)
In vivo quantification of regional dopamine‐D3 receptor binding potential of (+)‐PHNO: Studies in non‐human primates and transgenic mice (2009) (128)
Long-term trans-synaptic glial responses in the human thalamus after peripheral nerve injury (2001) (123)
PET-SORTEO: a Monte Carlo-based Simulator with high count rate capabilities (2004) (122)
Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration (2017) (118)
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats (2020) (114)
Neuroinflammation in treated HIV-positive individuals (2016) (114)
Quantification of the Specific Translocator Protein Signal of 18F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding (2013) (111)
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans (2015) (110)
Determination of [11C]PBR28 Binding Potential in vivo: A First Human TSPO Blocking Study (2014) (106)
Pittsburgh Compound B (11C-PIB) and Fluorodeoxyglucose (18 F-FDG) PET in Patients With Alzheimer Disease, Mild Cognitive Impairment, and Healthy Controls (2010) (104)
Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis (2016) (100)
Toward an improved prediction of human in vivo brain penetration (2008) (97)
Decreasing Amphetamine-Induced Dopamine Release by Acute Phenylalanine/Tyrosine Depletion: A PET/[11C]Raclopride Study in Healthy Men (2004) (97)
Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers (2015) (96)
Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo (2012) (96)
Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. (2015) (95)
Endogenous Opioid Release in the Human Brain Reward System Induced by Acute Amphetamine Administration (2012) (94)
Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635--explanation of high signal contrast in PET and an aid to biomathematical modelling. (1998) (93)
Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans (2011) (86)
In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with 18F-PBR111 PET (2014) (86)
Affinity and selectivity of [11C]‐(+)‐PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo (2012) (86)
Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. (2006) (85)
The Simplified Reference Tissue Model: Model Assumption Violations and Their Impact on Binding Potential (2015) (84)
Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. (2015) (82)
Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. (2001) (82)
A Statistical Method for the Analysis of Positron Emission Tomography Neuroreceptor Ligand Data (2000) (81)
Kinetic Modeling of 11C-SB207145 Binding to 5-HT4 Receptors in the Human Brain In Vivo (2009) (79)
Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. (2002) (77)
β-blocker Binding to Human 5-HT1A Receptors in vivo and in vitro: Implications for Antidepressant Therapy (2000) (77)
Amphetamine induced endogenous opioid release in the human brain detected with [¹¹C]carfentanil PET: replication in an independent cohort. (2014) (76)
A Biomathematical Modeling Approach to Central Nervous System Radioligand Discovery and Development (2009) (72)
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. (2003) (70)
Modeling Dynamic PET-SPECT Studies in the Wavelet Domain (2000) (67)
Comparison of four 11C-labeled PET ligands to quantify translocator protein 18 kDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176—based on recent publications that measured specific-to-non-displaceable ratios (2017) (66)
Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain (2016) (66)
Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET (2010) (66)
Orbitofrontal connectivity with resting-state networks is associated with midbrain dopamine D3 receptor availability. (2012) (65)
Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis (2017) (65)
Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. (2000) (63)
Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans (2001) (62)
A procedure for generating locally identifiable reparameterisations of unidentifiable non-linear systems by the similarity transformation approach. (1998) (57)
Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study (2019) (57)
Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [11C]PBR28 PET study (2017) (56)
Markov Random Field Models for Segmentation of PET Images (2001) (56)
Prediction of Repeat-Dose Occupancy from Single-Dose Data: Characterisation of the Relationship between Plasma Pharmacokinetics and Brain Target Occupancy (2011) (56)
Quantitative imaging of protein targets in the human brain with PET (2015) (55)
Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human (2014) (55)
Combining PET Biodistribution and Equilibrium Dialysis Assays to Assess the Free Brain Concentration and BBB Transport of CNS Drugs (2012) (54)
Quantification of Lung PET Images: Challenges and Opportunities (2017) (53)
Thermal Imaging Is a Noninvasive Alternative to PET/CT for Measurement of Brown Adipose Tissue Activity in Humans (2017) (53)
In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism (2014) (52)
Optimal design of pulsed arterial spin labeling MRI experiments (2008) (50)
Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Site in Human Brain (2014) (50)
Pindolol occupancy of 5‐HT1A receptors measured in vivo using small animal positron emission tomography with carbon‐11 labeled WAY 100635 (2000) (50)
11C-PBR28 and 18F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis (2017) (49)
Radiosynthesis and Characterization of 11C-GSK215083 as a PET Radioligand for the 5-HT6 Receptor (2012) (48)
PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers (2017) (48)
5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochlori (2002) (47)
Quantitative analysis of [carbonyl-(11)C]WAY-100635 PET studies. (2000) (47)
Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1 (2011) (46)
Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo11C-BU99008 PET study. (2019) (46)
Radiosynthesis and in vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. (2011) (45)
Brain lesion segmentation through image synthesis and outlier detection (2017) (44)
The PET radioligand [carbonyl-(11)C]desmethyl-WAY-100635 binds to 5-HT(1A) receptors and provides a higher radioactive signal than [carbonyl-(11)C]WAY-100635 in the human brain. (2002) (44)
In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury (2019) (44)
Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11]WAY-100635 and [11C]raclopride (2002) (44)
11C-GSK189254: A Selective Radioligand for In Vivo Central Nervous System Imaging of Histamine H3 Receptors by PET (2009) (43)
Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptor. (2003) (43)
Voxel-Based Analysis of 11C-PIB Scans for Diagnosing Alzheimer's Disease (2008) (42)
Benzodiazepine Site Pharmacokinetic/Pharmacodynamic Quantification in Man: Direct Measurement of Drug Occupancy and Effects on the Human Brain In Vivo (1996) (42)
11C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than 11C-(R)-PK11195 (2017) (41)
Characterization of 3 PET Tracers for Quantification of Mitochondrial and Synaptic Function in Healthy Human Brain: 18F-BCPP-EF, 11C-SA-4503, and 11C-UCB-J (2020) (41)
Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus (2018) (40)
Rank-shaping regularization of exponential spectral analysis for application to functional parametric mapping. (2003) (40)
In Vivo Binding of Antipsychotics to D3 and D2 Receptors: A PET Study in Baboons with [11C]-(+)-PHNO (2010) (39)
Mathematical modelling of [11C]-(+)-PHNO human competition studies (2013) (37)
PET studies in drug development: Methodological considerations. (2005) (37)
Guidelines for the content and format of PET brain data in publications and archives: A consensus paper (2020) (37)
A general method to correct PET data for tissue metabolites using a dual-scan approach. (2000) (36)
Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET (2008) (36)
PET Parametric Imaging: Past, Present, and Future (2020) (35)
Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system. (2019) (34)
Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation (2016) (34)
Repurposing the Microsoft Kinect for Windows v2 for external head motion tracking for brain PET (2015) (34)
Phosphodiesterase 10A in Schizophrenia: A PET Study Using [(11)C]IMA107. (2016) (33)
PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology (2018) (33)
Quantification in positron emission tomography for research in pharmacology and drug development. (2004) (32)
Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study) (2019) (32)
Measuring Neurotransmitter Release with PET: Methodological Issues (1998) (32)
Modelling the progression of Alzheimer's disease in MRI using generative adversarial networks (2018) (32)
Spatiotemporal Distribution of β-Amyloid in Alzheimer Disease Is the Result of Heterogeneous Regional Carrying Capacities (2017) (32)
Dynamic Positron Emission Tomography Data-Driven Analysis Using Sparse Bayesian Learning (2008) (32)
Behaviour of [11C]R(−)‐ and [11C]S(+)‐rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4 (2005) (31)
Preferential 5-HT1A Autoreceptor Occupancy by Pindolol is Attenuated in Depressed Patients: Effect of Treatment or an Endophenotype of Depression? (2004) (31)
Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers (2016) (31)
Non-invasive measurement of left ventricular volumes and function by gated positron emission tomography (1996) (31)
Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography (2010) (30)
A pharmacokinetic PET study of NK1 receptor occupancy (2012) (30)
Amyloid Load: A More Sensitive Biomarker for Amyloid Imaging (2018) (30)
Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. (2018) (29)
Adaptive‐Optimal Design in PET Occupancy Studies (2010) (29)
Unexpectedly high affinity of a novel histamine H3 receptor antagonist, GSK239512, in vivo in human brain, determined using PET (2014) (29)
A Graphical Method to Compare the in vivo Binding Potential of PET Radioligands in the Absence of a Reference Region: Application to [11C]PBR28 and [18F]PBR111 for TSPO Imaging (2014) (29)
Imaging in Central Nervous System Drug Discovery. (2017) (29)
Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load (2021) (28)
Molecular Imaging And Kinetic Analysis Toolbox (MIAKAT) - A Quantitative Software Package for the Analysis of PET Neuroimaging Data (2016) (28)
Statistical maps for EEG dipolar source localization (2005) (27)
Synthesis and Evaluation of [11C]SB207145 as the First In Vivo Serotonin 5-HT4 Receptor Radioligand for PET Imaging in Man (2008) (27)
Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: A positron emission tomography study in Papio anubis (2011) (27)
Relationship Between Glycine Transporter 1 Inhibition as Measured with Positron Emission Tomography and Changes in Cognitive Performances in Nonhuman Primates (2014) (27)
Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter (2019) (26)
A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261. (2004) (25)
Evidence for GABA‐A receptor dysregulation in gambling disorder: correlation with impulsivity (2016) (25)
Parametric Imaging of Ligand-Receptor Interactions Using a Reference Tissue Model and Cluster Analysis (1998) (25)
The impact of the rs6971 polymorphism in TSPO for quantification and study design (2015) (24)
Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge (2019) (24)
Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug‐Naive Parkinson's Disease (2020) (24)
Imaging Cortical Dopamine D1 Receptors Using [11C]NNC112 and Ketanserin Blockade of the 5-HT2A Receptors (2010) (24)
Loss of phosphodiesterase 4 in Parkinson disease (2017) (24)
Loss of phosphodiesterase 10 A expression is associated with progression and severity in Parkinson ’ s disease (2015) (23)
Parametrically defined cerebral blood vessels as non-invasive blood input functions for brain PET studies. (2004) (23)
Evaluation of novel N1-methyl-2-phenylindol-3-ylglyoxylamides as a new chemotype of 18 kDa translocator protein-selective ligand suitable for the development of positron emission tomography radioligands. (2011) (23)
Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis (2017) (23)
Evaluation of [O-methyl-11C]RS-15385-197 as a positron emission tomography radioligand for central α2-adrenoceptors (2000) (22)
PET measurement of the influence of corticosteroids on serotonin-1A receptor number (2001) (22)
Tracer Kinetic Modelling of the 5-HT1A Receptor Ligand [carbonyl-11C]WAY-100635 (1998) (22)
Accuracy and reliability of [11C]PBR28 specific binding estimated without the use of a reference region (2018) (21)
Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies. (2009) (21)
Eratum: Determination of [ 11 C]PBR28 binding potential in vivo: A first human TSPO blocking study (Journal of Cerebral Blood Flow and Metabolism (2014) 34 (1256)) (2014) (21)
Comparison of [11C]PBR28 and [18F]FEPPA as CNS peripheral benzodiazepine receptor PET ligands in the pig (2008) (21)
An evaluation of the brain distribution of [11C]GSK1034702, a muscarinic-1 (M1) positive allosteric modulator in the living human brain using positron emission tomography (2014) (20)
Quantitative analysis of dynamic 18F-FDG PET/CT for measurement of lung inflammation (2017) (20)
Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics (2020) (20)
Disease-related patterns of in vivo pathology in Corticobasal syndrome (2018) (20)
Quantification of [11C]Ro15-4513 GABAAα5 specific binding and regional selectivity in humans (2017) (20)
Imaging of Chemotherapy-Induced Acute Cardiotoxicity with 18F-Labeled Lipophilic Cations (2019) (19)
Real‐time adaptive sequential design for optimal acquisition of arterial spin labeling MRI data (2010) (19)
PET quantification of muscarinic cholinergic receptors with [N‐11C‐methyl]‐benztropine and application to studies of propofol‐induced unconsciousness in healthy human volunteers (2004) (19)
GANsfer Learning: Combining labelled and unlabelled data for GAN based data augmentation (2018) (19)
Human Kinetic Modeling of the 5HT6 PET Radioligand 11C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease (2015) (19)
Further evaluation of [11C]MP‐10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis (2015) (19)
Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [11C]MP-10 PET rodent imaging study with ex vivo confirmation (2014) (19)
Wavelet variance components in image space for spatiotemporal neuroimaging data (2005) (19)
Evaluation of NMDA Receptors in Vivo in Schizophrenic Patients with [123I]CNS 1261 and SPET (2003) (18)
Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1–Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using 11C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging (2016) (18)
The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study (2021) (18)
Suppression of Noise Artifacts in Spectral Analysis of Dynamic PET Data (1998) (18)
Nonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer's disease (2019) (17)
PET Image Reconstruction Using Physical and Mathematical Modelling For Time of Flight PET-MR Scanners in the STIR Library. (2020) (17)
2-[11C]Thymidine Positron Emission Tomography Reproducibility in Humans (2005) (17)
Altered PDE 10 A expression detectable early before symptomatic onset in Huntington ’ s disease (2015) (17)
Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals (2018) (16)
Kinetic Analysis of Drug–Target Interactions with PET for Characterization of Pharmacological Hysteresis (2013) (16)
Monoamine Transporter Occupancy of a Novel Triple Reuptake Inhibitor in Baboons and Humans Using Positron Emission Tomography (2013) (16)
Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET (2014) (16)
Biodistribution and Radiation Dosimetry of the Glycine Transporter-1 Ligand 11C-GSK931145 Determined from Primate and Human Whole-Body PET (2011) (15)
Building a database for brain 18 kDa translocator protein imaged using [11C]PBR28 in healthy subjects (2019) (15)
Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer’s disease (2019) (15)
Bootstrapped DEPICT for error estimation in PET functional imaging (2004) (15)
On-line measurement of exhaled [11C]CO2 during PET. (2000) (15)
Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451 (2018) (15)
Effects of Depression and Antidepressant Treatment (2016) (14)
Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer. (2011) (14)
Positron Emission Tomography Compartmental Models : A Basis Pursuit Strategy for Kinetic Modelling (2002) (14)
A new human (psycho)pharmacology tool: the multiple organs coincidences counter (MOCC) (1995) (14)
Imaging Activated Microglia in the Aging Human Brain (2001) (14)
DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats (2020) (13)
Impact of scatter correction on D2 receptor occupancy measurements using 123I-IBZM SPECT: Comparison to 11C-Raclopride PET (2010) (13)
Evaluation of the novel 5-HT6 receptor radioligand, [11C]GSK-215083 in human (2008) (13)
Impact of image-based motion correction on dopamine D3/D2 receptor occupancy—comparison of groupwise and frame-by-frame registration approaches (2015) (12)
Spatio-temporal pharmacokinetic model based registration of 4D PET neuroimaging data (2014) (12)
Role of 18F-fluorodeoxyglucose Positron Emission Tomography in the Monitoring of Inflammatory Activity in Crohn's Disease (2016) (12)
Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease (2019) (11)
Dopamine D2/D3 receptor abnormalities after traumatic brain injury and their relationship to post-traumatic depression (2019) (11)
Kinetic analysis of neuroreceptor binding using PET (2004) (11)
Venous Sinuses vs. On-Line Arterial Sampling as Input Functions in PET (2000) (11)
PET Tau and Amyloid-beta Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers (vol 60, pg 283, 2017) (2018) (10)
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images (2021) (10)
Test–retest variability and reference region-based quantification of 18F-BCPP-EF for imaging mitochondrial complex I in the human brain (2020) (10)
[11C]GSK931145: A new pet ligand for glycine transporter 1 (2008) (10)
Tracer kinetic modeling via basis pursuit (2002) (9)
A non-linear mixed effect modelling approach for metabolite correction of the arterial input function in PET studies (2013) (9)
Blood brain barrier permeability of [11C]loperamide in humans under normal and impaired P-glycoprotein function (2008) (9)
First evaluation of PET-based human biodistribution and radiation dosimetry of 11C-BU99008, a tracer for imaging the imidazoline2 binding site (2018) (8)
Advances in biomathematical modeling for PET neuroreceptor imaging. (2011) (8)
PET-MR Attenuation Correction in Dynamic Brain PET Using [11C]Cimbi-36: A Direct Comparison With PET-CT (2018) (8)
To lipophilicity and beyond—towards a deeper understanding of radioligand non-specific binding (2006) (8)
Molecular and functional neuroimaging of human opioid receptor pharmacology (2011) (8)
[11C]PHNO studies in rhesus monkey: In vivo affinity for D2 and D3 receptors and dosimetry (2009) (8)
The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. (2020) (8)
Reparameterisation of Unidentifiable Systems using the Taylor Series Approach (1997) (8)
Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals (2021) (8)
Contribution of D3 receptors to the in vivo binding of [11C]PHNO in the primate brain (2008) (7)
The role of P-glycoprotein on blood brain barrier permeability of [11C]Loperamide in humans (2008) (7)
Demonstration of clomipramine and venlafaxine occupation at serotonin reuptake sites in man in vivo (1997) (7)
Quantification of human brain PDE4 occupancy by GSK356278: A [11C](R)-rolipram PET study (2017) (7)
Longitudinal (18F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation (2019) (7)
Multi-atlas Approaches for Image Segmentation across Modality , Species and Application Area (2019) (7)
Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s disease (2022) (6)
D3 receptor assessment in vivo: PET with [11C]PHNO and SB-277011 (2008) (6)
TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans (2021) (6)
Mathematical modelling and identifiability applied to positron emission tomography data (1996) (6)
Non linear mixed effects analysis in PET PK-receptor occupancy studies (2013) (6)
RPM STATISTICS — A statistical tool for receptor parametric mapping (2001) (6)
Development and evaluation of [11C]GSK931145, a new PET ligand for imaging type 1 glycine transporters (GlyT1) in the living human brain (2008) (5)
Consensus Recommendations on the Use of 18F-FDG PET/CT in Lung Disease (2020) (5)
Spatial-temporal Pharmacokinetic Model Based Registration of 4D Brain PET Data (2012) (5)
Spatial Normalization of PET Ligand Images (1998) (5)
Comparison of Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer's disease, mild cognitive impairment, and healthy controls (2009) (4)
BRAIN SEROTONIN RELEASE IS REDUCED IN PATIENTS WITH DEPRESSION: A [11C]Cimbi-36 PET STUDY WITH A D-AMPHETAMINE CHALLENGE. (2022) (4)
Wavelet variance components in image space for spatio-temporal neuroimaging data (2003) (4)
Reproducibility of findings in modern PET neuroimaging: insight from the NRM2018 grand challenge (2021) (4)
Identification and interpretation of microparameters in neuroreceptor compartmental models (2004) (4)
A Generalised Spatio-Temporal Registration Framework for Dynamic PET Data: Application to Neuroreceptor Imaging (2013) (4)
Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [11C]PHNO PET (2021) (4)
Statistical estimation with Kronecker products in positron emission tomography (2005) (3)
Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human (2020) (3)
Neurons derived from individual early Alzheimer’s disease patients reflect their clinical vulnerability (2022) (3)
RELATIONSHIP BETWEEN ASTROCYTE ACTIVATION USING [11C]BU99008 PET, GLUCOSE METABOLISM AND AMYLOID IN ALZHEIMER’S DISEASE: A DEMENTIA PLATFORM UK EXPERIMENTAL MEDICINE STUDY (2018) (3)
Uptake of [N-methyl-11C]propionyl-L-carnitine (PLC) in human myocardium. (1996) (3)
In vivo binding of antipsychotics to D3 and D2 receptors: A PET study in baboons with [11C]-(+)-PHNO (2010) (3)
Imaging Type I Glycine Transporters in the CNS using Positron Emission Tomography (2014) (3)
A pseudo-reference region method applied to measurement of GlyT1 occupancy in human brain using [11C]GSK931145 and PET (2010) (3)
Small Animal PET Enables Parametric Mapping of Saturation Kinetics at the 5-HT1A Receptor (2001) (3)
Kinetic analysis of [11C]GSK189254, a novel radioligand for the H3 receptor in humans using positron emission tomography (PET) (2008) (3)
Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study (2021) (3)
Widespread cell stress and mitochondrial dysfunction in early Alzheimers Disease (2021) (3)
Joint estimation of subject motion and tracer kinetic parameters of dynamic PET data in an EM framework (2012) (3)
Simultaneous multiple kinect v2 for extended field of view motion tracking (2015) (3)
Acute acetate administration increases endogenous opioid levels in the human brain: A [11C]carfentanil molecular imaging study (2021) (3)
CHAPTER 52 – The Analysis of Brain PET Radioligand Displacement Studies (1996) (3)
Within-subject comparison of the sensitivity of [11C]-(+)-PHNO and [11C]raclopride to amphetamine induced changes in endogenous dopamine in healthy human volunteers (2010) (3)
DEEP AND FREQUENT PHENOTYPING: A FEASIBILITY STUDY FOR EXPERIMENTAL MEDICINE IN DEMENTIA (2017) (3)
Evaluation of the adenosine A2A receptor ligand [11C] SCH442416 in the rodent brain (2013) (3)
117.4 Pet Imaging of Neuroinflammation in Schizophrenia (2017) (3)
Parametrically defined cerebral blood vessels as non-invasive blood input functions for brain PET studies (2004) (2)
Parametric Definition of ROIs to Recover the Caliber of Cerebral Blood Vessels Directly from PET Images (2002) (2)
Tau pathology in early Alzheimer’s disease disrupts selective neurophysiological network dynamics (2019) (2)
MR-DTI and PET multimodal imaging of dopamine release within subdivisions of basal ganglia (2011) (2)
Attenuation of preferential occupancy of 5-HT1A autoreceptors by pindolol in depressed patients: effect of SSRIs or an endophenotype of the depressed state? (2002) (2)
P.3.008 Endogenous opioid release in pathological gamblers after an oral amphetamine challenge: a [C]carfentanil PET study (2014) (2)
PET neuroimaging: The elephant unpacks his trunk Comment on Cumming: “PET neuroimaging: The white elephant packs his trunk?” (2014) (2)
[18F]PBR111 binding is increased in lesional and peri-lesional white matter of MS patients (2013) (2)
A Supervised Method for PET Reference Region Extraction (2000) (2)
Chapter Eleven – Imaging the Dopamine D3 Receptor In Vivo (2014) (2)
[11C]raclopride pet detects dopamine release induced by behavioural manipulation (1998) (2)
Imaging cortical dopamine D 1 receptors using ( 11 C)NNC112 and ketanserin blockade of (2010) (2)
Abstract 1144: Imaging radiotherapy induced pulmonary fibrogenic changes with integrin-PET (2019) (2)
Uptake and regional distribution of [11C]rofecoxib in human brain (2010) (2)
Adaptive optimal design in pet occupancy studies (2009) (2)
Preclinical evaluation of [18F]FB-A20FMDV2 as a selective marker for measuring αVβ6 integrin occupancy using positron emission tomography in rodent lung (2020) (2)
Quantitative analysis of dynamic 18F-FDG in lungs of HV and COPD subjects (2016) (2)
Comparison of 3 F-18 TSPO ligands in non-human primates (2010) (2)
Simulation and Synthesis in Medical Imaging (2016) (2)
Thermal imaging as a novel non-invasive method to measure human brown adipose tissue activity in humans (2015) (2)
Implementation of Image Reconstruction for GE SIGNA PET/MR PET Data in the STIR Library (2018) (2)
Evaluation of the in vivo ED50 for the PET Radioligand, [11C]GSK-215083, in Papio anubis (2010) (2)
Quantification of dopamine release within the connectivity-derived functional subdivision of striatum (2012) (1)
Estimation of occupancy in the absence of baseline data and reference regions (2007) (1)
Awake nonhuman primate brain PET imaging without head restraint (2010) (1)
Model-based sequential human PET study design for Optimal PK/RO assessment (2007) (1)
P.361 Brain serotonin release reduced among patients with severe depression: a pet study with [11c]cimbi-36 and d-amphetamine challenge (2019) (1)
PET imaging of dopamine D3 receptors in humans with [11C]-(+)-PHNO: dissection of PHNO signal using two highly selective D3 antagonists (2010) (1)
EVALUATION OF NOVEL ASTROCYTE MARKER [11C]BU99008 PET IN ALZHEIMER’S DISEASE: A DEMENTIA PLATFORM U.K. EXPERIMENTAL MEDICINE STUDY (2018) (1)
Steps to a neurochemistry of personality (1999) (1)
Evaluation and correction of biases induced by the use of automated whole-blood measurements in TSPO PET studies using 11C-PBR28 (2016) (1)
Radioligand for the H 3 Receptor in Humans Using PET (2010) (1)
CHAPTER 5 – The MOC Counter: A Pharmacological Tool for the in Vivo Measurement of Ligand Occupancy Indices in the Human Brain (1996) (1)
Quantification of 11C-SB207145-PET for 5-HT4 receptors in the human brain: Preliminary results (2007) (1)
Statistical Based PET Partial Volume Correction (2002) (1)
Binding Potential of [18F]Setoperone: Reproducibility of Measures by the Simplified Reference Tissue Method (1998) (1)
A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18F-MK-6240 PET (2023) (1)
Principles of PET and Its Role in Understanding Drug Delivery to the Brain (2014) (1)
QUANTIFYING MITOCHONDRIAL AND SYNAPTIC FUNCTION IN ALZHEIMER’S DISEASE USING [18F]BCPP-EF, [11C]SA4503 AND [11C]UCB-J PET IMAGING (2019) (1)
Astrogliosis in aging and Parkinson’s disease dementia: a new clinical study with 11C-BU99008 PET (2022) (1)
A Visual Interpretation Algorithm for Assessing Brain Tauopathy with [18F]MK6240 Positron Emission Tomography (2022) (1)
An open-label study in healthy male volunteers using positron emission tomography to assess brain adenosine A2A receptor occupancy by V81444 (2013) (1)
A database of [11C]WAY-100635 binding in healthy volunteers: relationship to demographic, physiological and personality variables (2001) (1)
Evidence for Endogenous Dopamine Release Induced by Behavioural Manipulation (1998) (1)
NMDA dysfunction in schizophrenia is modulated by antipsychotic drugs: A [123I]CNS 1261 study (2004) (1)
PBR28, PBR06 and PBR111 bind two distinct TSPO sites in human brain tissue (2010) (1)
Imaging brain TSPO availability with [11C]PBR28 PET in patients with retroviral (HTLV1 and HIV-1) infection (2014) (1)
Investigation of Irreversible Reference Tissue Models for Parametric Imaging (1998) (1)
Characterising the relationship between plasma pharmacokinetics and occupancy following single dose allows prediction of repeat dose occupancy (2009) (1)
P.6.f.002 Endogenous opioid release in pathological gamblers after an oral amphetamine challenge: a [11C]carfentanil PET study (2014) (1)
Measuring in vivo receptor affinity: Comparison of methods using the H3 ligand [11C]GSK189254 in baboon (2010) (1)
The role of 18 F-fluorodeoxyglucose positron emission tomography in the monitoring of inflammatory activity in Crohn ’ s disease (2018) (1)
Imaging the dopamine D3/D2 receptor with [11C]PHNO: Development and validation of manual and automated regional analyses (2009) (1)
DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats (2020) (1)
In vivo evaluation and quantification of the 5-HT4 receptor PET ligand [11C]SB-207145 (2006) (1)
Using in vitro measurements of plasma and tissue free fractions to interpret radioligand uptake (2007) (0)
Brain PET Oral 4: in vivo Pharmacology I—Dopamine and Norepinephrine (2009) (0)
Quantification of dopamine release and dopamine D3R in the functional subdivisions of the human pallidum (2013) (0)
LV volumes and wall motion assessed with gated PET: Comparison with MUGA (1995) (0)
A bio-mathematical modelling approach to radioligand discovery and development (2009) (0)
A combined diffusion tensor imaging (DTI) and [11C]-(+)-PHNO positron emission tomography (PET) study to quantify dopamine D3/D2 receptors in pallidum (2010) (0)
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats (2020) (0)
Positron Emission Tomography - Tracer Kinetic Modelling in Drug Development (2006) (0)
S.07.08 Using Positron Emission Tomography to investigate microglial activation in alcohol dependence: preliminary findings (2013) (0)
Radiosynthesis and in vivo evaluation in the pig and baboon of candidate PDE10A PET radioligands (2013) (0)
Simplifying our understanding of SRTM (2013) (0)
Su1198 18F-FDG-PET Scanning As a Monitoring Tool in Crohn's Disease. A Prospective Study Assessing the Repeatability and Responsiveness of PET Endpoints (2015) (0)
A PET ANALYSIS PIPELINE FOR MEASURING MISFOLDED PROTEIN CONCENTRATIONS IN MULTICENTER IMAGING TRIALS USING MIAKATTM (2017) (0)
Gender and cognitive performance: Correlations to 5-HT4 receptors in the human brain: A 11C-SB207145-PET study (2008) (0)
PET TAU AND AMYLOID-BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER’S DISEASE: AN OBSERVATIONAL STUDY (2017) (0)
A PET ANALYSIS PIPELINE FOR MEASURING MISFOLDED PROTEIN CONCENTRATIONS IN MULTICENTER IMAGING TRIALS USING MIAKATTM (2017) (0)
sj-pdf-1-jcb-10.1177_0271678X20928149 - Supplemental material for Test–retest variability and reference region-based quantification of 18F-BCPP-EF for imaging mitochondrial complex I in the human brain (2020) (0)
Evidence of a Topographical and Inflammatory Brain response in Human T Lymphotropic virus type 1 associated myelopathy (HAM) (2014) (0)
A diffusion tensor imaging (DTI) and [11C]PHNO PET study to measure dopamine release in the functional subdivisions of the basal ganglia (2011) (0)
P.6.b.006 Alcohol dependent patients have blunted endogenous opioid release measured using [11C]carfentanil PET and dexamphetamine challenge (2016) (0)
Title: Nonlinear biomarker interactions in conversion from Mild Cognitive Impairment to Alzheimer’s disease (2019) (0)
BASELINE CHARACTERISTICS FOR PATIENTS WITH MILD ALZHEIMER’S DISEASE ENROLLED IN THE PHASE IIA TRIAL OF ACTIVE IMMUNOTHERAPEUTIC VACCINE UB-311 (2018) (0)
Corrigendum (2020) (0)
Optimal Experimental Design for receptor drug development with PET studies (2011) (0)
A quantitative molecular imaging analysis pipeline for PET oncology studies (2012) (0)
DEEP AND FREQUENT PHENOTYPING STUDY: PET AND MR IMAGING PROTOCOL (2017) (0)
Mitochondrial complex I availability is reduced in schizophrenia: a positron emission tomography study (2022) (0)
Dopaminergic and serotonergic systems imaged across species: Translation of the binding potential (2014) (0)
PET measurement of nicotine evoked dopamine release (2010) (0)
Dopamine D3 receptor availability explains orbitofrontal connectivity with cognitive networks (2010) (0)
Evaluation of Intraperitoneal [18F]-FDOPA Administration for Micro-PET Imaging in Mice and Assessment of the Effect of Subchronic Ketamine Dosing on Dopamine Synthesis Capacity (2022) (0)
Pharmacokinetic Modeling of Dynamic PET (2015) (0)
Differentiation of the Mu-opioid ligand GSK1521498 from naltrexone using [11C]carfentanil PET and fMRI (2010) (0)
Striatal dopamine D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET: A within-subject comparison study (2008) (0)
Brain PET Oral 2: Novel Radiotracers and Modeling (2009) (0)
Imaging pure dopamine D1 receptors with [11C]NNC112 PET and ketanserin challenge (2009) (0)
LOSS OF PHOSPHODIESTERASE 10A SIGNALLING IS ASSOCIATED WITH PROGRESSION AND SEVERITY IN PATIENTS WITH PARKINSON'S DISEASE (2016) (0)
Bolus/infusion studies for SPET quantification of [I-123]-CNS 1261 binding to NMDA receptors in vivo (2002) (0)
Evaluation of intraperitoneal [ 18 F]-FDOPA administration for micro-PET imaging in 1 mice and assessment of the effect of sub-chronic ketamine dosing on dopamine 2 synthesis capacity 3 (2022) (0)
Identification of the key characteristics of successful PET neuroimaging probes (2011) (0)
Rank-shaping regularization of exponential spectral analysis for application to functional parametric mapping (2003) (0)
Imaging synaptic microstructure and synaptic loss in vivo in early Alzheimers Disease (2021) (0)
DEEP AND FREQUENT PHENOTYPING STUDY: PET AND MR IMAGING PROTOCOL (2017) (0)
Characterising the performance of the simplified and pseudo reference tissue models (2011) (0)
Hippocampal Inflammation and Depressive Symptoms are Associated to the Strength of Hippocampal Functional Connectivity in Multiple Sclerosis: A Study with TSPO-PET and Resting-State fMRI (2015) (0)
In vivo evaluation of NMDA receptors in schizophrenia: An [I-123]CNS 1261 SPECT study (2004) (0)
[N-methyl-11C]propionyl-L-carnitine uptake in human myocardium (1995) (0)
Development of a bolus/infusion paradigm for the novel NMDA receptor tracer [I-123]CNS-1261 towards clinical studies in schizophrenia (2002) (0)
The role of phosphodiesterase 4 in sleep disturbances in Parkinson's disease (2017) (0)
Modeling of brain NK1 receptor binding-plasma concentration relationship with a novel NK1 antagonist (2009) (0)
Pharmacokinetic characterization of compounds with increased target residence times using PET (2010) (0)
Serotonergic pathology linked with the premotor phase of A53T α-synuclein 1 parkinsonism and with disease burden: cross-sectional studies (2019) (0)
PET Kinetic Modelling with Basis Pursuit 3 PET Kinetic Modelling with Basis Pursuit 3 Reversible Irreversible Plasm a R eference (2002) (0)
CALCULATION OF AβL WITH THE IQAβ ALGORITHM ENABLES AUTOMATIC AND REPRODUCIBLE CLASSIFICATION OF [18F]-FLORBETAPIR SCANS (2018) (0)
Predicting the in vivo performance of TSPO PET radioligands using a biomathematical modelling approach (2010) (0)
Phosphodiesterases and striatal pathways in Parkinson's disease (2017) (0)
Abstract LB-351: Evaluation of two engineered antibody fragments derived from a human CD20 antibody as tracers for immunoPET . (2013) (0)
Main title Longitudinal [18F]AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation. Authors (2019) (0)
A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimod (2023) (0)
Mapping NMDA receptors in vivo in humans with [1231]CNS-1261 SPET: Bolus versus bolus/infusion studies (2002) (0)
P1-265: Voxel-based analysis of C11 Pittsburgh compound B for diagnosing Alzheimer's disease (2008) (0)
Quantitative kinetic modelling of FDG in lung imaging of COPD (2015) (0)
P.4.024 Using positron emission tomography to investigate microglial activation in alcohol dependence: preliminary findings (2013) (0)
Investigation of acute modulation of cAMP in vivo with PET using [11C]rolipram (2005) (0)
PET evaluation of the TSPO ligands [F-18]FEPPA, [F-18]PRB06, and [F-18]PBR111 in nonhuman primate (2010) (0)
Kinetic modelling of the novel NMDA receptor tracer (ICNS)-I-123-1261 for SPET. (2001) (0)
In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease (2022) (0)
Hippocampal inflammation and depression in multiple sclerosis: integrating evidence from TSPO PET and resting state fMRI (2015) (0)
Radioligand discovery and development through bio-mathematical modelling (2009) (0)
A network-spreading model to characterize the accumulation of β-amyloid in Alzheimer’s Disease. (2015) (0)
Comparison of bolus and bolus/infusion studies for SPET quantification of [123I]-CNS 1261 binding to NMDA receptors in vivo (2002) (0)
Concurrent 3D super resolution on intensity and segmentation maps improves detection of structural effects in neurodegenerative disease (2023) (0)
Neuroinflammation and genesis of affective symptoms in multiple sclerosis: integrating evidence from TSPO PET and resting state FMRI (2016) (0)
Cortical [11C]PBR28 PET Measures of Microglial Inflammation Explain Differences in Cognitive Performance of People with MS (S41.005) (2016) (0)
P2-365 ADDED DIAGNOSTIC VALUE OF 18F- FLUTEMETAMOL PET SCANNING IN YOUNG PATIENTS WITH DEMENTIA QUANTIFYING MITOCHONDRIAL AND SYNAPTIC FUNCTION IN ALZHEIMER’S DISEASE USING 18 F]BCPP-EF, [ 11 AND [ 11 C]UCB-J PET IMAGING (2019) (0)
AMYLOID LOAD: A NOVEL BIOMARKER WITH INCREASED SENSITIVITY FOR β-AMYLOID (2017) (0)
Loss of phosphodiesterase 10A (PDE-10A) signalling is associated with progression and severity in patients with Parkinson’s disease (P6.081) (2015) (0)
Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers (2021) (0)
Effect of cellular compartments on the binding of [3H](+)PhNO to the porcine D2/D3-DAR (2010) (0)
O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS (2020) (0)
Comparison of two methods for quantification of NMDA receptor binding with [I-123]-CNS 1261: Venous sampling and equilibrium analysis versus arterial sampling and kinetic modelling (2002) (0)
In vivo translocator protein positron emission tomography imaging detects a heterogeneity of lesion inflammatory activity in multiple sclerosis not evident by MRI. (2016) (0)
Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations (2017) (0)
[18F]PBR111 binding in lesional and peri-lesional multiple sclerosis white matter (2013) (0)
Synaptic PET imaging using [11C]UCB‐J in frontotemporal dementia (2021) (0)
Positron emission tomography imaging in multiple sclerosis highlights a diffuse inflammatory response in brain that appears normal on conventional magnetic resonance imaging (2015) (0)
Application of Aligned-UMAP to longitudinal biomedical studies (2022) (0)
PET TAU AND AMYLOID-BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER’S DISEASE: AN OBSERVATIONAL STUDY (2017) (0)
Predicting the in vivo performance of PET radioligands through in silico modelling (2008) (0)
Determination of [11C]PBR28 binding potential in vivo: A first human TSPO occupancy study (2013) (0)
[11C](+)RX-821024: A novel tracer for imaging α2-adrenoceptors (2008) (0)
P.525 The relationship between synaptic density marker SV2A and glutamate: a multimodal positron emission tomography and magnetic resonance spectroscopy imaging study (2020) (0)
Oral presentations, Tuesday, October 18, 2005 (2005) (0)
In vivo pharmacological evaluation of the 5HT-1B radioligand [11C]P943 in nonhuman primates using PET (2008) (0)
Comparison of Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer's disease, Mild Cognitive Impairment and healthy controls (2009) (0)
Is the NMDA receptor relevant to antipsychotic drug action (2004) (0)
Erratum: Gait in mild Alzheimer's disease: Feasibility of multi-center measurement in the clinic and home with body-worn sensors: A pilot study (Journal of Alzheimer's Disease (2018) 63:1 (331-341) DOI: 10.3233/JAD-171116) (2018) (0)
Mixed Affinity Binding in Humans with 18 kDa Translocator Protein (TSPO) Ligands (2015) (0)
PROBABILISTIC METHODS FOR THE EEG INVERSE PROBLEM (2002) (0)
Neurons from individual early Alzheimer’s disease patients reflect their clinical vulnerability (2021) (0)
Analysis of Functional Imaging Data Sets via Functional Segmentation (2001) (0)
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [ 18 F]flutemetamol PET images: Neuroimaging / Optimal neuroimaging measures for early detection (2020) (0)
DEMENTIA PLATFORM U.K. EXPERIMENTAL MEDICINE: HUMAN IN VIVO ASTROGLIAL ACTIVATION IN EARLY ALZHEIMER’S DISEASE (2017) (0)
Determination of [11C]PBR28 Binding Potential in vivo: A First Human TSPO Blocking Study (2014) (0)
A graphical method for comparing the performance of radioligands (2013) (0)
Affinity of dopamine for the D3 and D2 high receptors in the human brain in vivo (2011) (0)
About Contact us My IOPscience You may also be interested in : PETPVC : a toolbox for performing partial volume correction techniques in positron emission tomography (2016) (0)
Brain inflammation in human T lymphotropic virus type-1-associated myelopathy (HAM): A multimodal 11C PBR 28 PET and MR DTI case study (2013) (0)
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol PET images (2020) (0)
P251 Correlation of FDG PET scanning with clinical and laboratory markers of activity in patients with Crohn's disease (2014) (0)
Graphical analysis of occupancy studies for radioligands with irreversible kinetics (2010) (0)
Towards a biomathematical screening tool for radioligand discovery and development (2008) (0)
P1-237: PET amyloid imaging with Pittsburgh compound B in Alzheimer's disease, mild cognitive impairment, and healthy controls (2008) (0)
S54.02 Using pet to study dopamine release in vivo (2000) (0)
AmyloidIQ: An advanced analytical algorithm to quantify amyloid‐PET [18F]NAV4694 scans (2020) (0)
Comparison of nonlinear mixed effects and conventional least squares analyses of PET PK-receptor occupancy studies (2010) (0)
Prediction of cognitive performance from IQ biomarkers and MR volumetrics in the ATN framework depends on diagnosis (2021) (0)
P-11-32 The multiple objects coincidences counter (MOCC) — a new tool for the measurement of ligand tissue occupancy in vivo in man (1995) (0)
PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH (2022) (0)
Optimal design in PET occupancy studies: a sensitivity study (2012) (0)
In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease (2022) (0)
Applications of Radiotracer Imaging Poster Abstracts (2012) (0)
TAUIQ: A QUANTITATIVE ALGORITHM TO INCREASE THE POWER OF TAU PET IMAGING IN CLINICAL TRIALS (2019) (0)
Characterising the temporal relationship between Aβ and tau accumulation in AD using in vivo imaging data (2020) (0)
Evidence of brain inflammation in patients with Human T Lymphotropic Virus type 1 associated myelopathy (HAM): A pilot, multi modal imaging study using [ 11 C] PBR28 PET, MR T1w and (2016) (0)
Bayesian kinetic modelling (2006) (0)
Brain phosphodiesterase 10A (PDE-10A) density in early premanifest HD gene carriers (2014) (0)
Quantification of Lung PET Images (2017) (0)
Adaptive Sequential Design for Optimal Scheduling of Continuous ASL Data Acquisition (2008) (0)
TAUIQ - A QUANTITATIVE ALGORITHM TO INCREASE THE POWER OF TAU PET IMAGING IN CLINICAL TRIALS (2019) (0)
4th International Conference on Bioelectromagnetism (2009) (0)
On-Line Measurement of Exhaled [11C]C02DuringPET (2006) (0)
Kinetic modelling of dissolution dynamic nuclear polarisation 13C magnetic resonance spectroscopy data for analysis of pyruvate delivery and fate in tumours (2021) (0)
A framework of incorporating variance estimates into wavelet analysis in PET metabolism and receptor studies (2005) (0)
Evidence for dopamine release during a videogame using [11C]Raclopride PET (1998) (0)
PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roger N. Gunn?

Roger N. Gunn is affiliated with the following schools: